Secukinumab effective in moderate-to-severe psoriasis

July 11, 2014
Secukinumab effective in moderate-to-severe psoriasis
For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.

(HealthDay)—For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.

Richard G. Langley, M.D., from Dalhousie University in Halifax, Canada, and colleagues assessed secukinumab in two phase 3 trials involving patients with moderate-to-severe plaque psoriasis. The Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis (ERASURE) trial involved 738 patients and the Full Year Investigative Examination of Secukinumab versus Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis (FIXTURE) study involved 1,306 patients. Patients were randomized to 300 mg or 150 mg subcutaneous secukinumab or placebo, or to etanercept in the FIXTURE study.

The researchers found that in both studies the proportion of patients who had a reduction of 75 percent or more from baseline in the psoriasis area-and-severity index score was higher with each secukinumab dose versus placebo or etanercept. The rates were 81.6 and 71.6 percent, respectively, with 300 and 150 mg of secukinumab, compared to 4.5 percent with placebo in the ERASURE study. In the FIXTURE study, the rates were 77.1 and 67.0 percent, respectively, with 300 and 150 mg of secukinumab, compared to 44.0 percent with and 4.9 percent with (P < 0.001 for secukinumab doses versus comparators).

"Secukinumab was effective for in two randomized trials, validating interleukin-17A as a therapeutic target," the authors write.

The study was funded by Novartis, the manufacturer of secukinumab.

Explore further: UVB preferred for treatment of moderate to severe psoriasis

More information: Full Text (subscription or payment may be required)

Related Stories

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012

(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Study compares effectiveness of psoriasis treatments

April 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Many psoriasis patients undertreated for CV risk factors

June 22, 2012

(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue of the Journal ...

Short/long-term analyses deem etanercept safe for psoriasis

July 29, 2012

(HealthDay) -- Etanercept treatment is well tolerated for psoriasis, with no indication of dose-related or cumulative toxicity in short- or long-term analyses, according to a study published in the August issue of the Journal ...

Reasons for discontinuation vary by psoriasis treatment

August 10, 2012

(HealthDay) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

Etanercept cuts sciatic pain from lumbar disc herniation

November 1, 2013

(HealthDay)—Compared with placebo, transforaminal injections of etanercept provide relief from leg and back pain in patients with symptomatic lumbar disc herniation (LDH), according to research published in the Nov. 1 issue ...

Recommended for you

Cellphone data can track infectious diseases

August 20, 2015

Tracking mobile phone data is often associated with privacy issues, but these vast datasets could be the key to understanding how infectious diseases are spread seasonally, according to a study published in the Proceedings ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.